- Chuanjin Wu, MDLaboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892Interests: Oncogenesis; Signal Transduction; Inflammatory Cytokines; T Cell Biology; Epithelial Biology; Molecular Basis of Genetic Diseases
Nearly a century ago, the discovery of the Warburg effect unveiled the link between oncogenesis and metabolism. Altered metabolism is found across a variety of cancer cell types. While normal cells typically depend on mitochondrial oxidation to meet their bioenergetic needs, cancer cells mostly utilize aerobic glycolysis for energy production and proliferative aggression. The discovery and subsequent vigorous investigation of oncogenes and tumor suppressors have brought enormous progress to the understanding of cancer pathogenesis. Mutations or expression changes in oncogenes and tumor suppressors are widely reported to alter metabolic pathways to fuel cancer pathogenicity. Many of the signaling pathways that drive tumorigenesis directly regulate cellular metabolism. In addition to oncogene-driven metabolic reprogramming, the oncometabolites themselves modulate cell signaling and differentiation and promote metastasis of cancer cells. Metabolic preprogramming is widely considered as a hallmark of cancer.
Nevertheless, tumor heterogeneity and complexity present tremendous challenges to the profound understanding of cancer metabolism. Solid tumors are disorganized, being populated with many cell types including stromal fibroblasts, endothelial cells from blood vessels, immune cells, and malignant cancer cells. Accumulating evidence has illustrated the importance of comprehending bilateral interactions between a primary tumor and its microenvironment. Metabolic alterations and interactions represent an attractive therapeutic target for cancer and encouraging results with drugs targeting metabolic processes have been obtained. A recent landmark achievement of cancer research is the clinical application of immunotherapy. The tumor microenvironment tends to be immunosuppressive, enabling cancer immune evasion. It has been increasingly recognized that cancer metabolism modulates local immune response. The cancer cell metabolites may suppress tumor immunity by regulating T cell function directly or through crippling antigen presenting cells, primarily dendritic cells. An in-depth understanding of cancer metabolic landscape will be necessary to find more effective cancer therapies.
This Special Issue is centered around all the various aspects of metabolic crosstalk in cancer and aims to compile a collection of original and review articles on this topic. We particularly welcome the submissions that address the modulation of immune microenvironment by cancer metabolism.
Dr. Chuanjin Wu
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Metabolic cross-talk between ovarian cancer and the tumor microenvironment—providing potential targets for cancer therapyYi Lin, Xiao Liang, Xijie Zhang, Yanghong Ni, ... Xia ZhaoFront. Biosci. (Landmark Ed) 2022, 27(4), 139; https://doi.org/10.31083/j.fbl2704139114Download304Views
- Targeting the Key Enzymes of Abnormal Fatty Acid β-oxidation as a Potential Strategy for Tumor TherapyHongdan Chen, Zeyu Yang, Yiceng Sun, Supeng Yin, ... Fan ZhangFront. Biosci. (Landmark Ed) 2022, 27(3), 95; https://doi.org/10.31083/j.fbl270309556Download1Citations186Views
- CARD9 as a potential therapeutic target in lung cancerRuanmei Sheng, Zhiwen YangFront. Biosci. (Landmark Ed) 2021, 26(12), 1621–1626; https://doi.org/10.52586/505558Download160Views
- Molecular subtype classification of breast cancer using established radiomic signature models based on F-FDG PET/CT imagesJianjing Liu, Haiman Bian, Yufan Zhang, Yongchang Gao, ... Wengui XuFront. Biosci. (Landmark Ed) 2021, 26(9), 475–484; https://doi.org/10.52586/496042Download3Citations109Views